(1.20%) 5 070.55 points
(0.69%) 38 504 points
(1.59%) 15 697 points
(-0.02%) $83.34
(-0.22%) $1.808
(-0.33%) $2 334.40
(-0.19%) $27.31
(-0.04%) $922.40
(-0.03%) $0.934
(-0.17%) $10.89
(-0.03%) $0.803
(0.02%) $93.20
@ $1.954
Issued: 14 Feb 2024 @ 09:32
Return: -26.56%
Previous signal: Feb 7 - 16:00
Previous signal:
Return: 1.24 %
Live Chart Being Loaded With Signals
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers...
Stats | |
---|---|
Today's Volume | 347 605 |
Average Volume | 482 053 |
Market Cap | 50.21M |
EPS | $0 ( 2024-04-04 ) |
Next earnings date | ( $-0.370 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.450 |
ATR14 | $0.00600 (0.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Fortress Biotech, Inc. | Buy | 193 905 | COMMON STOCK, PAR VALUE $0.0001 |
2024-03-12 | Amit Sharma | Sell | 0 | Common Stock (Restricted) |
2024-02-28 | Oliviero James F Iii | Sell | 5 894 | COMMON STOCK |
2024-02-28 | Oliviero James F Iii | Sell | 9 056 | COMMON STOCK |
2024-02-28 | Gray William Garrett | Sell | 2 035 | Common Stock |
INSIDER POWER |
---|
82.37 |
Last 98 transactions |
Buy: 5 337 828 | Sell: 1 367 663 |
Volume Correlation
Checkpoint Therapeutics Correlation
10 Most Positive Correlations | |
---|---|
RMRM | 0.94 |
TLGT | 0.938 |
SVAC | 0.937 |
AGFY | 0.934 |
PAIC | 0.934 |
CCCC | 0.931 |
ALT | 0.931 |
JOAN | 0.93 |
VERU | 0.928 |
EYEG | 0.922 |
10 Most Negative Correlations | |
---|---|
NETE | -0.95 |
MMAC | -0.934 |
STAY | -0.927 |
BNIXU | -0.92 |
CCRC | -0.92 |
NVCN | -0.912 |
DSPG | -0.911 |
XM | -0.909 |
FEXD | -0.901 |
AVEO | -0.896 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Checkpoint Therapeutics Correlation - Currency/Commodity
Checkpoint Therapeutics Financials
Annual | 2023 |
Revenue: | $103 000 |
Gross Profit: | $103 000 (100.00 %) |
EPS: | $-2.77 |
Q4 | 2023 |
Revenue: | $6 000.00 |
Gross Profit: | $6 000.00 (100.00 %) |
EPS: | $-0.700 |
Q3 | 2023 |
Revenue: | $31 000.00 |
Gross Profit: | $31 000.00 (100.00 %) |
EPS: | $-0.290 |
Q2 | 2023 |
Revenue: | $31 000.00 |
Gross Profit: | $-13.91M (-44 883.87 %) |
EPS: | $-1.050 |
Financial Reports:
No articles found.
Checkpoint Therapeutics
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators